1. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;Eur. J. Cancer,2011
2. Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors;Abboud;Support Care Cancer,2018
3. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study;Ahmed;Clin. Pharmacol. Therap.,2010
4. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens;Bassi;Blood Transfus.,2015
5. Bayesian confidence propagation neural network;Bate;Drug Saf.,2007